Ind. Code § 35-48-2-10

Current through P.L. 171-2024
Section 35-48-2-10 - Schedule IV
(a) The controlled substances listed in this section are included in schedule IV.
(b) Narcotic drugs. Unless specifically excepted in a rule adopted by the board or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in the following limited quantities:
(1) Not more than 1 milligram of difenoxin (9618) and not less than 25 micrograms of atropine sulfate per dosage unit.
(2) Dextropropoxyphene (alpha- (+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane (9278).
(c) Depressants. Unless specifically excepted in a rule adopted by the board or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

Alfaxalone (2731).

Alprazolam (2882).

Barbital (2145).

Brexanolone (2400).

Bromazepam (2748).

Camazepam (2749).

Carisoprodol.

Chloral betaine (2460).

Chloral hydrate (2465).

Chlordiazepoxide (2744).

Clobazam (2751).

Clonazepam (2737).

Clorazepate (2768).

Clotiazepam (2752).

Cloxazolam (2753).

Daridorexant (2410).

Delorazepam (2754).

Diazepam (2765).

Dichloralphenazone (2467).

Estazolam (2756).

Ethchlorvynol (2540).

Ethinamate (2545).

Ethyl loflazepate (2758).

Fludiazepam (2759).

Flunitrazepam (2763).

Flurazepam (2767).

Fospropofol (2138).

Halazepam (2762).

Haloxazolam (2771).

Ketazolam (2772).

Lemborexant (2245).

Loprazolam (2773).

Lorazepam (2885).

Lormetazepam (2774).

Mebutamate (2800).

Medazepam (2836).

Meprobamate (2820).

Methohexital (2264).

Methylphenobarbital (mephobarbital) (2250).

Midazolam (2884).

Nimetazepam (2837).

Nitrazepam (2834).

Nordiazepam (2838).

Oxazepam (2835).

Oxazolam (2839).

Paraldehyde (2585).

Petrichloral (2591).

Phenobarbital (2285).

Pinazepam (2883).

Prazepam (2764).

Quazepam (2881).

Remimazolam (2846).

Suvorexant (2223).

Temazepam (2925).

Tetrazepam (2886).

Triazolam (2887).

Zaleplon (2781).

Zolpidem (Ambien) (2783).

Zopiclone (2784).

Zuranolone (2420).

(d) Stimulants. Unless specifically excepted in a rule adopted by the board or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

Cathine ((+)-norpseudoephedrine) (1230).

Diethylpropion (1610).

Fencamfamin (1760).

Fenproporex (1575).

Mazindol (1605).

Mefenorex (1580).

Modafinil (1680).

Pemoline (including organometallic complexes and chelates thereof) (1530).

Phentermine (1640).

Pipradrol (1750).

Serdexmethylphenidate (1729).

Sibutramine (1675).

Solriamfetol (2-amino-3-phenylpropyl carbamate; benzenepropanol, beta-amino-, carbamate (ester)) (1650).

SPA ((-)-1-dimethylamino-1,2-diphenylethane (1635).

(e) Other substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances including its salts:

Butorphanol (including its optical isomers) (9720).

Pentazocine (9709).

(f) Tramadol (Ultram).
(g) The board may except by rule any compound, mixture, or preparation containing any depressant substance listed in subsection (b), (c), (d), or (e), from the application of any part of this article if the compound, mixture, or preparation contains one (1) or more active medicinal ingredients not having a depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a depressant effect on the central nervous system.

IC 35-48-2-10

Amended by P.L. 84-2024,SEC. 5, eff. 7/1/2024.
Amended by P.L. 48-2023,SEC. 6, eff. 7/1/2023.
Amended by P.L. 56-2015, SEC. 5, eff. 4/23/2015.
Amended by P.L. 283-2013, SEC. 3, eff. 7/1/2013.
As added by Acts1976 , P.L. 148, SEC.7. Amended by Acts1977 , P.L. 344, SEC.2; Acts1979 , P.L. 303, SEC.6; Acts1981 , P.L. 170, SEC.5; P.L. 333-1983, SEC.4; P.L. 77-1984, SEC.14; P.L. 200-1987, SEC.12; P.L. 288-2001, SEC.17; P.L. 8-2004, SEC.3; P.L. 22-2008, SEC.4.